Genetic Testing Services Market Analysis – 2023
Browse Complete Market Details at: http://www.transparencymarketresearch.com/genetic-testing-services-market.html
Direct-to-customer genetic testing still continues to restrict the market growth due to mixed reviews on permissibility. In November 2013, FDA implemented a ban on marketing of direct-to-customer genetic testing services provided by 23andMe for its saliva based test. FDA argues that the company must seek an approval for the medical device. Various articles also criticize that the direct-to-customer genetic testing service is not fruitful, and is clearly a waste of money. Direct-to-customer companies provide testing services to consumers, without involvement of physician in primary checkup. Genetic makeup alone is a poor predictors of common diseases hence the approach is likely to lead people receiving potentially harmful treatment. Lack of proper counseling also misleads people about healthcare services and also builds incorrect perceptions about the genetic testing services. This may prove to be potential threat to the future market growth. Although currently direct-to-customer testing is a small segment of the genetic testing services market, the service providers are constantly trying to become an integral part of clinical care.
Get Sample Report Containing the Future Market Perspectives at: http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=10235
Majority of the genetic testing market is dominated by the U.S. market owing to higher disposable income, and increased awareness about the service. Major companies operating in the U.S. who provide genetic testing services include 23andMe, DNA Direct, Genova Diagnostics, GeneLink, and Interleukin Genetics. Reimbursement remains a barrier for the adoption of the service. The service on the other hand is expected to spur the concept of “evidence based coverage”. This will not only benefit the insurance provider but also provide necessary leverage for market growth. High cost of the service is a major hurdle for the market to enter Asia-Pacific and other countries. But with increasing per capita income and gradual development of healthcare sector in countries such as India and China, the market is expected to grow rapidly in the near future in these regions. Fully developed medical sector of Japan will serve as a gateway in the Asia-Pacific market.
Transparency Market Research (TMR) is a global market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. TMR’s experienced team of Analysts, Researchers, and Consultants, use proprietary data sources and various tools and techniques to gather and analyze information.
Our data repository is continuously updated and revised by a team of research experts, so that it always reflects the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.
90 State Street, Suite 700
Albany, NY 12207
USA - Canada Toll Free: 866-552-3453
This release was published on openPR.
Permanent link to this press release:
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Genetic Testing Services Market Analysis – 2023 here
News-ID: 516085 • Views: 190
More Releases from TMR - Research Reports
Pulmonary Drugs Market is Expected to Reach US$ 28,082.1 Million by the End of 2 …
According to the research report, the global pulmonary drugs market is expected to be worth US$ 28,082.1 mn by the end of 2024 as compared to US$ 48,039.7 mn in 2015. Analysts calculate that the global market will plummet at a CAGR of -6.3% during the forecast period of 2016 and 2024. The market will thrive as the demand for combination drugs is anticipated to remain on the rise during
North America Ventricular Assist Device Market is rising to a valuation of US$ 1 …
According to TMR, the opportunity in the North America market for VADs, which stood at US$0.4 bn in 2015, is likely to expand at a healthy CAGR of 9.20% between 2016 and 2024 and increase to US$1.07 bn by the end of the forecast period. The destination therapy (DT) segment has been reporting a greater application of VADs than the other two indication segments. It is expected to remain the
Dental Membrane and Bone Graft Substitutes Market to rise to US$ 922.6 Million b …
Transparency Market Research notes that innovation and expansion into emerging regions have served these companies well in strengthening their hold in the dental membrane and bone graft substitutes market. For instance, Switzerland-based Geistlich Pharma AG - a global manufacturer and supplier of dental products and devices - expanded its operations in Sydney, Australia and New Delhi, India in 2016. The global dental membrane and bone graft substitutes market is expected to
Human Vaccines Market is Estimated to Reach US$ 72.5 Billion by 2024
The global human vaccines market was valued at US$28.3 bn in 2015 and is estimated to reach US$72.5 bn by 2024, registering an 11.2% CAGR during the forecast period. By age group, pediatric vaccines accounted for a 57.5% share in the global human vaccines market in 2015. Adult vaccines, on the other hand, are expected to expand at a 13.2% CAGR from 2016 to 2024. Based on product, the pneumococcal segment
More Releases for Genetic
Preimplantation Genetic Testing Market is Blooming Worldwide
HTF MI recently introduced Global Preimplantation Genetic Testing Market study with in-depth overview, describing about the Product / Industry Scope and elaborates market outlook and status to 2023. At present, the market is developing its presence and some of the key players from the complete study are F. Hoffmann-La Roche, Abbott Laboratories, Thermo Fisher Scientific, Natera, Illumina & Perkin Elmer etc. The market Study is segmented by key regions which
Genetic Analysis ASProduct Pipeline Analysis, 2017 Update
"The Report Genetic Analysis ASProduct Pipeline Analysis, 2017 Update provides information on pricing, market analysis, shares, forecast, and company profiles for key industry participants. - MarketResearchReports.biz" About Genetic Analysis ASProduct Market Genetic Analysis AS (Genetic Analysis) is a molecular diagnostic company that mapping of microbiota by utilizing the GA-map technology to develop IVD tests in various diseases. The company develops gene-based routine tests for the mapping and diagnosis of
Preimplantation Genetic Diagnosis: Scope & Revenue Outlook
Rising numbers of assisted reproductive procedures such as in vitro fertilization (IVF) is Asia is the most prominent factor driving the market for preimplantation genetic diagnosis. This is, in essence, the result of factors such as the delayed age of conception among Asian women, the rising rate of infertility among the population, and the significantly expanding medical tourism industry in the region. Rising disposable incomes and increased awareness regarding the
India Genetic Testing Market Analysis
India is witnessing an accelerating shift towards the prevalence of non-communicable diseases, having secured third position in congenital malformations and genetic disorders as the commonest causes of mortality in neonates in cities. The ability to identify these non-communicable diseases at an early stage lies within the genetic screening segment. Genetic screening, however, is still in its infancy and there are many challenges that need to be overcome in order to
Preimplantation Genetic Diagnosis - Saving Offsprings From Any Genetic Disorder
The market for preimplantation genetic diagnosis (PGD) in Asia features high fragmentation when it comes to diagnostic service providers. The large number of local players has intensified the competitive rivalry in the region. However, owing to the lack of better alternatives to PGD, costs of these procedures remain high, a major limiting factor for the market, especially in cost-sensitive developing countries in the region. A recent report by TMR suggests that
Genetic Engineering – Influence of EU Population Growing
National movements campaigning against genetic engineering are helping to democratise the EU. That was the result of a recently completed Austrian Science Fund FWF project led by an independent researcher. According to the study\'s results, the almost simultaneous mobilisation of national populations reinforces public protest at a European level. The project therefore provides an optimistic outlook for the growing influence of the general population on EU decision-making processes. The controversy surrounding